Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Osurnia Patent Expiration

Osurnia is a drug owned by DECHRA, LTD. It is protected by 8 US drug patents filed from 2022 to 2027. Out of these, 5 patents are active and 3 patents have expired. Details of Osurnia’s patents and their expiration are given below.

Filter patents by

Country : United States (US)
Patent Category : All
Drug Patent Number Drug Patent Expiry Status
Patent Data
US7858115 23 Feb, 2027 Active
US7846472 19 Nov, 2026 Active
US7622138 21 Sep, 2026 Active
US8361496 09 Jan, 2025 Expired
US7404964 31 Oct, 2022 Expired
US6887487 31 Oct, 2022 Expired

Exclusivity Information

Osurnia holds 1 exclusivity out of which 1 has expired. Details of Osurnia's exclusivity codes and their expiration dates are given below.

Drug Exclusivity Drug Exclusivity Expiration
NCI Nov 04, 2017

About Osurnia

Osurnia is a drug owned by DECHRA, LTD. Osurnia uses Betamethasone Acetate, Florfenicol, Terbinafine as the active ingredients.

Active Ingredient:

Osurnia uses Betamethasone Acetate, Florfenicol, Terbinafine as the active ingredients. Check out other Drugs and Companies using Betamethasone Acetate, Florfenicol, Terbinafine ingredient.